nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—DCLK3—urine—adrenal gland cancer	0.0276	0.0724	CbGeAlD
Ruxolitinib—RET—parathyroid gland—adrenal gland cancer	0.0152	0.0398	CbGeAlD
Ruxolitinib—ANKK1—adrenal gland—adrenal gland cancer	0.0075	0.0196	CbGeAlD
Ruxolitinib—PRKG2—pituitary gland—adrenal gland cancer	0.00695	0.0182	CbGeAlD
Ruxolitinib—PLK1—gonad—adrenal gland cancer	0.00639	0.0168	CbGeAlD
Ruxolitinib—RPS6KA6—pituitary gland—adrenal gland cancer	0.00624	0.0163	CbGeAlD
Ruxolitinib—MAST1—pituitary gland—adrenal gland cancer	0.00624	0.0163	CbGeAlD
Ruxolitinib—CAMK1—adrenal cortex—adrenal gland cancer	0.00603	0.0158	CbGeAlD
Ruxolitinib—DCLK3—pituitary gland—adrenal gland cancer	0.00591	0.0155	CbGeAlD
Ruxolitinib—PRKCE—adrenal gland—adrenal gland cancer	0.0058	0.0152	CbGeAlD
Ruxolitinib—PLK1—adrenal gland—adrenal gland cancer	0.00557	0.0146	CbGeAlD
Ruxolitinib—PLK3—cardiac atrium—adrenal gland cancer	0.00533	0.014	CbGeAlD
Ruxolitinib—PLK3—pituitary gland—adrenal gland cancer	0.00521	0.0136	CbGeAlD
Ruxolitinib—CAMK1—gonad—adrenal gland cancer	0.00499	0.0131	CbGeAlD
Ruxolitinib—JAK1—adrenal cortex—adrenal gland cancer	0.00494	0.013	CbGeAlD
Ruxolitinib—CAMK1—pituitary gland—adrenal gland cancer	0.00487	0.0128	CbGeAlD
Ruxolitinib—DAPK2—adrenal cortex—adrenal gland cancer	0.00472	0.0124	CbGeAlD
Ruxolitinib—PLK3—adrenal gland—adrenal gland cancer	0.00465	0.0122	CbGeAlD
Ruxolitinib—CLK2—adrenal cortex—adrenal gland cancer	0.00439	0.0115	CbGeAlD
Ruxolitinib—TAOK2—pituitary gland—adrenal gland cancer	0.00437	0.0115	CbGeAlD
Ruxolitinib—CAMK1—adrenal gland—adrenal gland cancer	0.00435	0.0114	CbGeAlD
Ruxolitinib—MARK2—adrenal gland—adrenal gland cancer	0.00422	0.0111	CbGeAlD
Ruxolitinib—JAK1—gonad—adrenal gland cancer	0.00409	0.0107	CbGeAlD
Ruxolitinib—JAK1—cardiac atrium—adrenal gland cancer	0.00409	0.0107	CbGeAlD
Ruxolitinib—PLK4—gonad—adrenal gland cancer	0.00407	0.0107	CbGeAlD
Ruxolitinib—JAK1—pituitary gland—adrenal gland cancer	0.00399	0.0105	CbGeAlD
Ruxolitinib—DCLK1—pituitary gland—adrenal gland cancer	0.00399	0.0105	CbGeAlD
Ruxolitinib—CAMK1D—cardiac atrium—adrenal gland cancer	0.00399	0.0105	CbGeAlD
Ruxolitinib—PHKG2—gonad—adrenal gland cancer	0.00397	0.0104	CbGeAlD
Ruxolitinib—TAOK2—adrenal gland—adrenal gland cancer	0.00391	0.0102	CbGeAlD
Ruxolitinib—DAPK2—cardiac atrium—adrenal gland cancer	0.0039	0.0102	CbGeAlD
Ruxolitinib—CAMK1D—pituitary gland—adrenal gland cancer	0.0039	0.0102	CbGeAlD
Ruxolitinib—HIPK2—gonad—adrenal gland cancer	0.00382	0.01	CbGeAlD
Ruxolitinib—STK16—pituitary gland—adrenal gland cancer	0.00375	0.00982	CbGeAlD
Ruxolitinib—DAPK3—cardiac atrium—adrenal gland cancer	0.00367	0.00961	CbGeAlD
Ruxolitinib—CLK2—gonad—adrenal gland cancer	0.00364	0.00953	CbGeAlD
Ruxolitinib—CLK2—cardiac atrium—adrenal gland cancer	0.00363	0.00952	CbGeAlD
Ruxolitinib—JAK3—adrenal gland—adrenal gland cancer	0.00359	0.00941	CbGeAlD
Ruxolitinib—DAPK3—pituitary gland—adrenal gland cancer	0.00358	0.00939	CbGeAlD
Ruxolitinib—JAK1—adrenal gland—adrenal gland cancer	0.00357	0.00935	CbGeAlD
Ruxolitinib—DCLK1—adrenal gland—adrenal gland cancer	0.00357	0.00935	CbGeAlD
Ruxolitinib—CLK2—pituitary gland—adrenal gland cancer	0.00355	0.0093	CbGeAlD
Ruxolitinib—PLK4—adrenal gland—adrenal gland cancer	0.00355	0.00929	CbGeAlD
Ruxolitinib—ROCK1—gonad—adrenal gland cancer	0.00353	0.00924	CbGeAlD
Ruxolitinib—CAMK1D—adrenal gland—adrenal gland cancer	0.00348	0.00913	CbGeAlD
Ruxolitinib—PHKG2—adrenal gland—adrenal gland cancer	0.00346	0.00907	CbGeAlD
Ruxolitinib—DYRK1A—gonad—adrenal gland cancer	0.00344	0.00901	CbGeAlD
Ruxolitinib—BMPR2—cardiac atrium—adrenal gland cancer	0.00342	0.00896	CbGeAlD
Ruxolitinib—DAPK2—adrenal gland—adrenal gland cancer	0.0034	0.00892	CbGeAlD
Ruxolitinib—STK16—adrenal gland—adrenal gland cancer	0.00335	0.00878	CbGeAlD
Ruxolitinib—BMPR2—pituitary gland—adrenal gland cancer	0.00334	0.00876	CbGeAlD
Ruxolitinib—HIPK2—adrenal gland—adrenal gland cancer	0.00333	0.00873	CbGeAlD
Ruxolitinib—MAP3K7—adrenal cortex—adrenal gland cancer	0.00333	0.00872	CbGeAlD
Ruxolitinib—TYK2—adrenal cortex—adrenal gland cancer	0.00327	0.00857	CbGeAlD
Ruxolitinib—MKNK2—adrenal cortex—adrenal gland cancer	0.00323	0.00845	CbGeAlD
Ruxolitinib—DAPK3—adrenal gland—adrenal gland cancer	0.0032	0.00839	CbGeAlD
Ruxolitinib—NUAK2—pituitary gland—adrenal gland cancer	0.00319	0.00837	CbGeAlD
Ruxolitinib—CLK2—adrenal gland—adrenal gland cancer	0.00317	0.00831	CbGeAlD
Ruxolitinib—BMP2K—gonad—adrenal gland cancer	0.00306	0.00803	CbGeAlD
Ruxolitinib—LRRK2—gonad—adrenal gland cancer	0.00304	0.00796	CbGeAlD
Ruxolitinib—DYRK1A—adrenal gland—adrenal gland cancer	0.003	0.00785	CbGeAlD
Ruxolitinib—CYP3A4—urine—adrenal gland cancer	0.003	0.00785	CbGeAlD
Ruxolitinib—CAMK2G—pituitary gland—adrenal gland cancer	0.00299	0.00784	CbGeAlD
Ruxolitinib—BMPR2—adrenal gland—adrenal gland cancer	0.00298	0.00782	CbGeAlD
Ruxolitinib—LRRK2—pituitary gland—adrenal gland cancer	0.00296	0.00776	CbGeAlD
Ruxolitinib—MAP3K3—adrenal cortex—adrenal gland cancer	0.00287	0.00751	CbGeAlD
Ruxolitinib—NUAK2—adrenal gland—adrenal gland cancer	0.00285	0.00747	CbGeAlD
Ruxolitinib—MAP3K2—gonad—adrenal gland cancer	0.00278	0.00729	CbGeAlD
Ruxolitinib—MAP3K7—cardiac atrium—adrenal gland cancer	0.00275	0.00721	CbGeAlD
Ruxolitinib—TYK2—cardiac atrium—adrenal gland cancer	0.0027	0.00708	CbGeAlD
Ruxolitinib—MAP3K7—pituitary gland—adrenal gland cancer	0.00269	0.00705	CbGeAlD
Ruxolitinib—MKNK2—gonad—adrenal gland cancer	0.00267	0.007	CbGeAlD
Ruxolitinib—BMP2K—adrenal gland—adrenal gland cancer	0.00267	0.007	CbGeAlD
Ruxolitinib—CAMK2G—adrenal gland—adrenal gland cancer	0.00267	0.007	CbGeAlD
Ruxolitinib—MKNK2—cardiac atrium—adrenal gland cancer	0.00267	0.00699	CbGeAlD
Ruxolitinib—LRRK2—adrenal gland—adrenal gland cancer	0.00265	0.00694	CbGeAlD
Ruxolitinib—TYK2—pituitary gland—adrenal gland cancer	0.00264	0.00692	CbGeAlD
Ruxolitinib—TAOK3—adrenal cortex—adrenal gland cancer	0.00261	0.00685	CbGeAlD
Ruxolitinib—MKNK2—pituitary gland—adrenal gland cancer	0.00261	0.00683	CbGeAlD
Ruxolitinib—RET—pituitary gland—adrenal gland cancer	0.00254	0.00666	CbGeAlD
Ruxolitinib—JAK2—gonad—adrenal gland cancer	0.00246	0.00645	CbGeAlD
Ruxolitinib—JAK2—cardiac atrium—adrenal gland cancer	0.00246	0.00645	CbGeAlD
Ruxolitinib—MAP3K2—adrenal gland—adrenal gland cancer	0.00243	0.00636	CbGeAlD
Ruxolitinib—JAK2—pituitary gland—adrenal gland cancer	0.0024	0.0063	CbGeAlD
Ruxolitinib—MAP3K7—adrenal gland—adrenal gland cancer	0.0024	0.0063	CbGeAlD
Ruxolitinib—MAP3K3—gonad—adrenal gland cancer	0.00237	0.00622	CbGeAlD
Ruxolitinib—MAP3K3—cardiac atrium—adrenal gland cancer	0.00237	0.00621	CbGeAlD
Ruxolitinib—TYK2—adrenal gland—adrenal gland cancer	0.00236	0.00618	CbGeAlD
Ruxolitinib—MKNK2—adrenal gland—adrenal gland cancer	0.00233	0.0061	CbGeAlD
Ruxolitinib—IRAK1—adrenal gland—adrenal gland cancer	0.00233	0.0061	CbGeAlD
Ruxolitinib—MAP3K3—pituitary gland—adrenal gland cancer	0.00232	0.00607	CbGeAlD
Ruxolitinib—RET—adrenal gland—adrenal gland cancer	0.00227	0.00595	CbGeAlD
Ruxolitinib—TAOK3—cardiac atrium—adrenal gland cancer	0.00216	0.00566	CbGeAlD
Ruxolitinib—JAK2—adrenal gland—adrenal gland cancer	0.00215	0.00562	CbGeAlD
Ruxolitinib—TAOK3—pituitary gland—adrenal gland cancer	0.00211	0.00553	CbGeAlD
Ruxolitinib—MAP3K3—adrenal gland—adrenal gland cancer	0.00207	0.00542	CbGeAlD
Ruxolitinib—TAOK3—adrenal gland—adrenal gland cancer	0.00189	0.00494	CbGeAlD
Ruxolitinib—CAMK2G—Immune System—BAD—adrenal gland cancer	7.4e-05	0.00012	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GNRH1—adrenal gland cancer	7.39e-05	0.00012	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—EGFR—adrenal gland cancer	7.39e-05	0.000119	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—CTNNB1—adrenal gland cancer	7.38e-05	0.000119	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—BRAF—adrenal gland cancer	7.32e-05	0.000118	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SPRY2—adrenal gland cancer	7.32e-05	0.000118	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PRKACA—adrenal gland cancer	7.31e-05	0.000118	CbGpPWpGaD
Ruxolitinib—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	7.28e-05	0.000118	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—EGFR—adrenal gland cancer	7.23e-05	0.000117	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—BAD—adrenal gland cancer	7.23e-05	0.000117	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IGF2—adrenal gland cancer	7.21e-05	0.000117	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—BAD—adrenal gland cancer	7.21e-05	0.000117	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GNRH1—adrenal gland cancer	7.17e-05	0.000116	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—GNAS—adrenal gland cancer	7.15e-05	0.000116	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PRKACA—adrenal gland cancer	7.09e-05	0.000115	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—PTGS2—adrenal gland cancer	7.07e-05	0.000114	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—EGFR—adrenal gland cancer	7e-05	0.000113	CbGpPWpGaD
Ruxolitinib—PLK1—Cell Cycle—TP53—adrenal gland cancer	6.98e-05	0.000113	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IGF1R—adrenal gland cancer	6.97e-05	0.000113	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SPRY2—adrenal gland cancer	6.96e-05	0.000113	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—BAD—adrenal gland cancer	6.92e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—POMC—adrenal gland cancer	6.88e-05	0.000111	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—BAD—adrenal gland cancer	6.82e-05	0.00011	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—EGFR—adrenal gland cancer	6.79e-05	0.00011	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CDC42—adrenal gland cancer	6.79e-05	0.00011	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—BRAF—adrenal gland cancer	6.79e-05	0.00011	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TSHR—adrenal gland cancer	6.79e-05	0.00011	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SPRY2—adrenal gland cancer	6.76e-05	0.000109	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PRKACA—adrenal gland cancer	6.75e-05	0.000109	CbGpPWpGaD
Ruxolitinib—PRKCE—Hemostasis—TP53—adrenal gland cancer	6.74e-05	0.000109	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MEN1—adrenal gland cancer	6.7e-05	0.000108	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—EGFR—adrenal gland cancer	6.69e-05	0.000108	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—CTNNB1—adrenal gland cancer	6.62e-05	0.000107	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—EGFR—adrenal gland cancer	6.62e-05	0.000107	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TSHR—adrenal gland cancer	6.59e-05	0.000107	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SPRY2—adrenal gland cancer	6.56e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—POMC—adrenal gland cancer	6.51e-05	0.000105	CbGpPWpGaD
Ruxolitinib—PLK4—Cell Cycle—TP53—adrenal gland cancer	6.51e-05	0.000105	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—GNAS—adrenal gland cancer	6.49e-05	0.000105	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	6.47e-05	0.000105	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—POMC—adrenal gland cancer	6.41e-05	0.000104	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PRKACA—adrenal gland cancer	6.4e-05	0.000104	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TSHR—adrenal gland cancer	6.39e-05	0.000103	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CDC42—adrenal gland cancer	6.39e-05	0.000103	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MEN1—adrenal gland cancer	6.38e-05	0.000103	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CDC42—adrenal gland cancer	6.31e-05	0.000102	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PRKACA—adrenal gland cancer	6.3e-05	0.000102	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CTNNB1—adrenal gland cancer	6.22e-05	0.000101	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TERT—adrenal gland cancer	6.22e-05	0.000101	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CDC42—adrenal gland cancer	6.2e-05	0.0001	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MEN1—adrenal gland cancer	6.19e-05	0.0001	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—EGFR—adrenal gland cancer	6.15e-05	9.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF2—adrenal gland cancer	6.09e-05	9.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PRKACA—adrenal gland cancer	6.07e-05	9.81e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—GNAS—adrenal gland cancer	6.03e-05	9.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CDC42—adrenal gland cancer	6.02e-05	9.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MEN1—adrenal gland cancer	6.01e-05	9.71e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TERT—adrenal gland cancer	6e-05	9.71e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—EGFR—adrenal gland cancer	5.99e-05	9.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—EGFR—adrenal gland cancer	5.94e-05	9.61e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—POMC—adrenal gland cancer	5.92e-05	9.57e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF1R—adrenal gland cancer	5.88e-05	9.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—BAD—adrenal gland cancer	5.86e-05	9.48e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CTNNB1—adrenal gland cancer	5.85e-05	9.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—EGFR—adrenal gland cancer	5.84e-05	9.45e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—POMC—adrenal gland cancer	5.82e-05	9.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CDC42—adrenal gland cancer	5.73e-05	9.26e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—adrenal gland cancer	5.69e-05	9.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CDC42—adrenal gland cancer	5.67e-05	9.16e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—BAD—adrenal gland cancer	5.63e-05	9.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GNRH1—adrenal gland cancer	5.6e-05	9.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PRKACA—adrenal gland cancer	5.54e-05	8.96e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—CTNNB1—adrenal gland cancer	5.54e-05	8.95e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—PTGS2—adrenal gland cancer	5.48e-05	8.87e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CDC42—adrenal gland cancer	5.43e-05	8.78e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—BAD—adrenal gland cancer	5.41e-05	8.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—GNAS—adrenal gland cancer	5.41e-05	8.75e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CDC42—adrenal gland cancer	5.34e-05	8.64e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CTNNB1—adrenal gland cancer	5.31e-05	8.59e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CTNNB1—adrenal gland cancer	5.29e-05	8.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—EGFR—adrenal gland cancer	5.25e-05	8.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF2—adrenal gland cancer	5.24e-05	8.47e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—BAD—adrenal gland cancer	5.22e-05	8.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—GNAS—adrenal gland cancer	5.19e-05	8.39e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF2—adrenal gland cancer	5.15e-05	8.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—EGFR—adrenal gland cancer	5.15e-05	8.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CDC42—adrenal gland cancer	5.14e-05	8.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SPRY2—adrenal gland cancer	5.12e-05	8.28e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PRKACA—adrenal gland cancer	5.12e-05	8.27e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—GNAS—adrenal gland cancer	5.1e-05	8.26e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TERT—adrenal gland cancer	5.07e-05	8.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF1R—adrenal gland cancer	5.06e-05	8.19e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CTNNB1—adrenal gland cancer	5.04e-05	8.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TSHR—adrenal gland cancer	4.99e-05	8.07e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF1R—adrenal gland cancer	4.98e-05	8.05e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EGFR—adrenal gland cancer	4.93e-05	7.97e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—BRAF—adrenal gland cancer	4.93e-05	7.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—GNAS—adrenal gland cancer	4.92e-05	7.95e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CTNNB1—adrenal gland cancer	4.91e-05	7.93e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—adrenal gland cancer	4.89e-05	7.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CTNNB1—adrenal gland cancer	4.89e-05	7.91e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PRKACA—adrenal gland cancer	4.87e-05	7.87e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CTNNB1—adrenal gland cancer	4.87e-05	7.87e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—POMC—adrenal gland cancer	4.81e-05	7.78e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CTNNB1—adrenal gland cancer	4.75e-05	7.69e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—BRAF—adrenal gland cancer	4.75e-05	7.69e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CTNNB1—adrenal gland cancer	4.74e-05	7.67e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PRKACA—adrenal gland cancer	4.73e-05	7.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDC42—adrenal gland cancer	4.7e-05	7.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MEN1—adrenal gland cancer	4.69e-05	7.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—EGFR—adrenal gland cancer	4.66e-05	7.53e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EGFR—adrenal gland cancer	4.64e-05	7.5e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—EGFR—adrenal gland cancer	4.61e-05	7.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TERT—adrenal gland cancer	4.59e-05	7.43e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PRKACA—adrenal gland cancer	4.59e-05	7.41e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CTNNB1—adrenal gland cancer	4.48e-05	7.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BAD—adrenal gland cancer	4.46e-05	7.21e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—BAD—adrenal gland cancer	4.41e-05	7.13e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EGFR—adrenal gland cancer	4.39e-05	7.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—POMC—adrenal gland cancer	4.37e-05	7.06e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TERT—adrenal gland cancer	4.36e-05	7.05e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDC42—adrenal gland cancer	4.34e-05	7.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BAD—adrenal gland cancer	4.33e-05	7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TERT—adrenal gland cancer	4.29e-05	6.93e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EGFR—adrenal gland cancer	4.21e-05	6.81e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BAD—adrenal gland cancer	4.2e-05	6.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—CTNNB1—adrenal gland cancer	4.2e-05	6.79e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EGFR—adrenal gland cancer	4.19e-05	6.78e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—adrenal gland cancer	4.14e-05	6.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDC42—adrenal gland cancer	4.13e-05	6.68e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—POMC—adrenal gland cancer	4.06e-05	6.57e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—BRAF—adrenal gland cancer	4.01e-05	6.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDC42—adrenal gland cancer	4.01e-05	6.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—BAD—adrenal gland cancer	4e-05	6.46e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—adrenal gland cancer	3.99e-05	6.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF2—adrenal gland cancer	3.98e-05	6.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—adrenal gland cancer	3.98e-05	6.44e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—GNAS—adrenal gland cancer	3.95e-05	6.38e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—adrenal gland cancer	3.89e-05	6.29e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDC42—adrenal gland cancer	3.89e-05	6.29e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—adrenal gland cancer	3.89e-05	6.29e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—adrenal gland cancer	3.89e-05	6.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—adrenal gland cancer	3.87e-05	6.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF2—adrenal gland cancer	3.87e-05	6.25e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	3.86e-05	6.25e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CTNNB1—adrenal gland cancer	3.86e-05	6.24e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—adrenal gland cancer	3.86e-05	6.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1R—adrenal gland cancer	3.85e-05	6.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—GNAS—adrenal gland cancer	3.83e-05	6.2e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—BAD—adrenal gland cancer	3.79e-05	6.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—adrenal gland cancer	3.77e-05	6.09e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—adrenal gland cancer	3.76e-05	6.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF2—adrenal gland cancer	3.75e-05	6.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1R—adrenal gland cancer	3.74e-05	6.04e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—BAD—adrenal gland cancer	3.73e-05	6.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GNAS—adrenal gland cancer	3.72e-05	6.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CTNNB1—adrenal gland cancer	3.71e-05	5.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—POMC—adrenal gland cancer	3.64e-05	5.89e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—BRAF—adrenal gland cancer	3.64e-05	5.88e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1R—adrenal gland cancer	3.62e-05	5.86e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—adrenal gland cancer	3.61e-05	5.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRKACA—adrenal gland cancer	3.58e-05	5.79e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CTNNB1—adrenal gland cancer	3.56e-05	5.76e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—adrenal gland cancer	3.55e-05	5.74e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—adrenal gland cancer	3.52e-05	5.69e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—POMC—adrenal gland cancer	3.49e-05	5.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TERT—adrenal gland cancer	3.48e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SDHB—adrenal gland cancer	3.46e-05	5.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—BRAF—adrenal gland cancer	3.45e-05	5.58e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—POMC—adrenal gland cancer	3.44e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CTNNB1—adrenal gland cancer	3.44e-05	5.56e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—BRAF—adrenal gland cancer	3.39e-05	5.49e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—adrenal gland cancer	3.34e-05	5.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—adrenal gland cancer	3.32e-05	5.38e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TERT—adrenal gland cancer	3.31e-05	5.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—POMC—adrenal gland cancer	3.31e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—adrenal gland cancer	3.29e-05	5.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BAD—adrenal gland cancer	3.28e-05	5.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TERT—adrenal gland cancer	3.22e-05	5.2e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TERT—adrenal gland cancer	3.12e-05	5.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—adrenal gland cancer	3.06e-05	4.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDC42—adrenal gland cancer	3.04e-05	4.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BAD—adrenal gland cancer	3.03e-05	4.9e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—adrenal gland cancer	2.94e-05	4.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—adrenal gland cancer	2.94e-05	4.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CTNNB1—adrenal gland cancer	2.93e-05	4.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF2—adrenal gland cancer	2.93e-05	4.74e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GNAS—adrenal gland cancer	2.9e-05	4.7e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CTNNB1—adrenal gland cancer	2.9e-05	4.69e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BAD—adrenal gland cancer	2.88e-05	4.66e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTNNB1—adrenal gland cancer	2.85e-05	4.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1R—adrenal gland cancer	2.83e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—adrenal gland cancer	2.82e-05	4.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BAD—adrenal gland cancer	2.8e-05	4.53e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTNNB1—adrenal gland cancer	2.76e-05	4.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—BRAF—adrenal gland cancer	2.76e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—adrenal gland cancer	2.74e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—adrenal gland cancer	2.72e-05	4.4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BAD—adrenal gland cancer	2.71e-05	4.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—POMC—adrenal gland cancer	2.66e-05	4.3e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CTNNB1—adrenal gland cancer	2.63e-05	4.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—BRAF—adrenal gland cancer	2.62e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—POMC—adrenal gland cancer	2.58e-05	4.17e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—BRAF—adrenal gland cancer	2.55e-05	4.12e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—POMC—adrenal gland cancer	2.5e-05	4.05e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—adrenal gland cancer	2.49e-05	4.03e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—BRAF—adrenal gland cancer	2.47e-05	4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—adrenal gland cancer	2.47e-05	3.99e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—adrenal gland cancer	2.45e-05	3.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—adrenal gland cancer	2.44e-05	3.94e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—adrenal gland cancer	2.32e-05	3.76e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—adrenal gland cancer	2.3e-05	3.71e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—adrenal gland cancer	2.29e-05	3.7e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—adrenal gland cancer	2.26e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—adrenal gland cancer	2.23e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SDHD—adrenal gland cancer	2.23e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—RRM1—adrenal gland cancer	2.23e-05	3.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—adrenal gland cancer	2.19e-05	3.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—adrenal gland cancer	2.16e-05	3.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BAD—adrenal gland cancer	2.12e-05	3.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—adrenal gland cancer	2.08e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—adrenal gland cancer	1.99e-05	3.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—adrenal gland cancer	1.98e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—adrenal gland cancer	1.96e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—adrenal gland cancer	1.94e-05	3.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—adrenal gland cancer	1.93e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—adrenal gland cancer	1.93e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—adrenal gland cancer	1.9e-05	3.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—adrenal gland cancer	1.87e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—adrenal gland cancer	1.84e-05	2.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—adrenal gland cancer	1.79e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—adrenal gland cancer	1.71e-05	2.77e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MED12—adrenal gland cancer	1.66e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—adrenal gland cancer	1.66e-05	2.68e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—adrenal gland cancer	1.63e-05	2.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—adrenal gland cancer	1.58e-05	2.55e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—adrenal gland cancer	1.5e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—adrenal gland cancer	1.46e-05	2.36e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—adrenal gland cancer	1.41e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—adrenal gland cancer	1.4e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—adrenal gland cancer	1.26e-05	2.04e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—adrenal gland cancer	1.22e-05	1.98e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	1.21e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—adrenal gland cancer	1.19e-05	1.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—adrenal gland cancer	1.11e-05	1.79e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNAS—adrenal gland cancer	9.82e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	9.63e-06	1.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—adrenal gland cancer	9.28e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—adrenal gland cancer	6.61e-06	1.07e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	5.27e-06	8.52e-06	CbGpPWpGaD
